Engineering personalized micro-tumor ecosystems

设计个性化微肿瘤生态系统

基本信息

  • 批准号:
    10261573
  • 负责人:
  • 金额:
    $ 61.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-21 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Abstract Cancer is one of the leading causes of death in the United States, accounting for near 1 in every 4 deaths. However, despite the recent development of subtype-specific personalized therapy based on achievements in the fields of molecular and genetic profiling, many cancer treatments still have low efficacy which mostly arise from the limited ability to predict the patient tumor responses to therapeutic agents. The major reason that current therapeutics often cannot translate into a successful clinical outcomes is because of the complex tumor microenvironment and heterogeneity that limit the predictive power of the biomarker-guided strategies for chemotherapy. Therefore, the successful engineering of personalized three-dimensional (3D) tumor ecosystem that can recapitulate the tumor microenvironment and heterogeneity in vitro is strongly desired to accurately predict patients’ responses to anti-cancer drugs and thus further improve patient outcome. Here we propose to develop a personalized breast-cancer-ecosystem-on-a-chip platform for personalized screening of cancer chemotherapeutics with high accuracy by utilizing patient-derived tumor explant, defined tumor grade-matched biomaterial matrices and autologous patient serum to mimic patient-specific tumor hallmarks. The proposed cancer-ecosystem-on-a-chip will also be tightly regulated under physiological fluid dynamics. In this project, we have hypothesized that 1) the use of tumor explant will embrace the critical components of the tumor heterogeneity of the patient, 2) the combination of defined tumor grade-matched matrix, autologous patient serum, and a microfluidic bioreactor will prevent the phenotype alteration of the tumor explant, and 3) the integration of a machine-learning algorithm with the cancer-ecosystem-on-a-chip platform will provide more accurate, unbiased prediction of the patient responses to chemotherapeutics based on the data gathered from the engineered tumor model. Our preliminary results show that the combination of tumor explant culture and tumor-derived matrix constituents had predicted therapeutic responses with 100% sensitivity. Our preliminary results show high specificity throughout a range of cancers including breast cancer, colorectal cancer, and head and neck squamous cell carcinoma, and thus the findings can have broad applications, and can emerge as a paradigm shift in the management of cancer.
摘要 癌症是美国的主要死亡原因之一,占每4例死亡中的近1例。 然而,尽管最近发展了亚型特异性个性化治疗, 尽管在分子和遗传分析领域,许多癌症治疗仍然具有低功效, 因为预测患者肿瘤对治疗剂的反应的能力有限。目前, 治疗往往不能转化为一个成功的临床结果是因为复杂的肿瘤 微环境和异质性限制了生物标志物指导策略的预测能力, 化疗因此,个性化三维(3D)肿瘤生态系统的成功工程 强烈希望能够在体外重现肿瘤微环境和异质性, 预测患者对抗癌药物的反应,从而进一步改善患者的预后。在此,我们建议 开发一个个性化的乳腺癌生态系统芯片平台,用于癌症的个性化筛查 通过使用患者来源的肿瘤外植体,定义的肿瘤等级匹配, 生物材料基质和自体患者血清以模拟患者特异性肿瘤标志。拟议 芯片上的癌症生态系统也将在生理流体动力学下受到严格调节。本课题 我假设1)使用肿瘤外植体将包括肿瘤的关键成分 患者的异质性,2)定义的肿瘤等级匹配基质,自体患者 血清,并且微流体生物反应器将防止肿瘤外植体的表型改变,以及3) 机器学习算法与癌症生态系统芯片平台的集成将提供更多 根据从以下方面收集的数据,准确、无偏地预测患者对化疗药物的反应: 工程肿瘤模型。我们的初步结果表明,肿瘤外植体培养和 肿瘤来源的基质成分预测了100%灵敏度的治疗反应。我们的初步 结果显示,在包括乳腺癌、结肠直肠癌和头颈癌在内的一系列癌症中, 和颈部鳞状细胞癌,因此,研究结果可以有广泛的应用,并可以成为一个 癌症管理的模式转变。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer.
  • DOI:
    10.1158/0008-5472.can-19-4036
  • 发表时间:
    2020-12-01
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Smalley M;Natarajan SK;Mondal J;Best D;Goldman D;Shanthappa B;Pellowe M;Dash C;Saha T;Khiste S;Ramadurai N;Eton EO;Smalley JL;Brown A;Thayakumar A;Rahman M;Arai K;Kohandel M;Sengupta S;Goldman A
  • 通讯作者:
    Goldman A
Convex Calibrated Surrogates for the Multi-Label F-Measure
Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions.
  • DOI:
    10.1002/smll.202004282
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jiang X;Ren L;Tebon P;Wang C;Zhou X;Qu M;Zhu J;Ling H;Zhang S;Xue Y;Wu Q;Bandaru P;Lee J;Kim HJ;Ahadian S;Ashammakhi N;Dokmeci MR;Wu J;Gu Z;Sun W;Khademhosseini A
  • 通讯作者:
    Khademhosseini A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ali Khademhosseini其他文献

Ali Khademhosseini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ali Khademhosseini', 18)}}的其他基金

Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
  • 批准号:
    10397659
  • 财政年份:
    2021
  • 资助金额:
    $ 61.49万
  • 项目类别:
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
  • 批准号:
    10384769
  • 财政年份:
    2021
  • 资助金额:
    $ 61.49万
  • 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
  • 批准号:
    10620134
  • 财政年份:
    2021
  • 资助金额:
    $ 61.49万
  • 项目类别:
Drug eluting injectable biomaterials for next generation chemoembolization
用于下一代化疗栓塞的药物洗脱可注射生物材料
  • 批准号:
    10230909
  • 财政年份:
    2021
  • 资助金额:
    $ 61.49万
  • 项目类别:
Healing enterocutaneous fistulas using bioengineered biomaterials
使用生物工程生物材料治愈肠皮瘘
  • 批准号:
    10532787
  • 财政年份:
    2021
  • 资助金额:
    $ 61.49万
  • 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
  • 批准号:
    10171610
  • 财政年份:
    2018
  • 资助金额:
    $ 61.49万
  • 项目类别:
Treatment of arterial aneurysms using an injectable biomaterial
使用可注射生物材料治疗动脉瘤
  • 批准号:
    9883832
  • 财政年份:
    2018
  • 资助金额:
    $ 61.49万
  • 项目类别:
Engineering personalized micro-tumor ecosystems
设计个性化微肿瘤生态系统
  • 批准号:
    9981696
  • 财政年份:
    2017
  • 资助金额:
    $ 61.49万
  • 项目类别:
Targeted chemotherapy delivery and capture
靶向化疗递送和捕获
  • 批准号:
    9913518
  • 财政年份:
    2017
  • 资助金额:
    $ 61.49万
  • 项目类别:
Engineering personalized micro-tumor ecosystems
设计个性化微肿瘤生态系统
  • 批准号:
    9756346
  • 财政年份:
    2017
  • 资助金额:
    $ 61.49万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了